Organic Active Ingredients TRIZ Cases

A timed supplement regimen using antioxidants, tryptophan, and tyrosine reduces postpartum depression severity without antidepressant side effects.

Selective M1/M3 agonists combined with cycloplegics improve near vision while maintaining distance acuity and reducing ciliary spasms.

Ethyl acetate and hexane solvent mixtures crystallize vitamin D3 to exclude contaminants, overcoming chromatography time consumption.

Eleutheroside B modulates astrocyte and microglia activation to reduce pro-inflammatory cytokines, addressing ineffective current therapies.

Merging propolis with carnosic acid creates a synergistic formulation that overcomes antifungal resistance while accelerating pathogen elimination.

Novel 5-amino-4-hydroxypentoyl amides act as potent HIV protease inhibitors with reduced plasma protein binding.

Targeting BALIR-2 lincRNA expression enables early detection and reduces toxicity compared to conventional chemotherapy.

Combining agomelatine with a norepinephrine reuptake inhibitor creates a synergistic pharmaceutical composition.

Specific sugar chain structures lacking sialic acid at non-reducing terminals regulate DCIR signaling to treat bone metabolic disorders.

Screening for GSTT1 enzyme levels before treatment prevents lymphopenia and reduces infection risk during monomethyl fumarate therapy.

Selective antibodies recognize conformational changes in misfolded SOD1, resolving the trade-off between treatment safety and targeting specificity.

Controlled heating at 50-95°C with homogenization prevents particle growth and drug degradation during glucocorticosteroid suspension sterilization.

Modified nucleic acids mimic HULC and Pair lncRNAs to increase phenylalanine hydroxylase binding affinity.

Rho kinase inhibitors replace surgical resection by restoring vascular integrity, reducing cerebral cavernous malformation growth and rupture risk.

Novel phenothiazine diaminium salts improve stability and absorption for neurodegenerative disease treatment.

Hydrophilic HASA-gel matrix maintains homeopathic compounds in an aqueous environment, extending localized treatment duration for severe injuries.

Porous composite punctal plugs sustain drug release to halt vision loss without frequent dosing.

Replacing hazardous acetone cyanohydrin with sodium hydroxide in THF reduces impurity formation and improves yield.

Imidazopyridyl compounds inhibit CYP11B2 selectively, avoiding sexual side effects and hyperkalemia from nonselective receptor antagonists.

A controlled release formulation uses a superabsorbent polymer core to trap microparticles within a hard gel structure.

A paliperidone matrix uses carbomer and polyethylene oxide to provide sustained drug release over 12 to 24 hours.

RNAi agents inhibit HSET to kill cancer cells with extra centrosomes while sparing normal cells.

An acrylic acid-based water-soluble polymer prevents separation in oil-based solid compositions containing polyhydric alcohol dispersants.

Non-viral circular DNA vectors lacking bacterial origins deliver therapeutic genes for long-term episomal expression.

Novel heterocyclic bisphenol compounds modulate androgen receptor activity to enable precise radiopharmaceutical imaging of prostate cancer tissues.

The (S)-enantiomer of mepazine inhibits the MALT1 paracaspase enzyme with high affinity.

Small molecule biaryl compounds replace monoclonal antibodies to block PD-1/PD-L1 signaling, reducing therapy complexity and manufacturing costs.

5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives inhibit CDK8 protein kinase activity.

A condensation process in N-methylpyrrolidone followed by alcoholic reflux isolates rilpivirine hydrochloride monohydrate with high purity.

Conjugating Streptococcus pneumoniae polysaccharides to diphtheria toxin fragment B creates multivalent immunogenic compositions.

Topical allopurinol cream inhibits xanthine oxidase to prevent chemotherapy-induced skin toxicity and maintain treatment efficacy.

Very low molecular weight heparins with optimized monosaccharide ratios reduce bleeding risk while enhancing tissue regeneration in diabetic foot ulcers.

Heterobifunctional compounds degrade MDM2 protein, restoring p53 activity and inhibiting cell proliferation in cancer models.

Self-inducing gellan gum hydrogels promote tri-lineage stem cell differentiation through controlled molecular weight and chemical modifications.

Sanguisorba officinalis extract binds PD-L1 on cancer cells to activate T cells and inhibit tumor proliferation.

Ginsenoside M1 mediates crystal interactions to prevent NLRP3 inflammasome activation, reducing interleukin-1β and alleviating gout inflammation.

A novel small molecule compound designed to treat ischemic stroke by selectively modulating receptor activation pathways.

Converting low melting point active pharmaceutical ingredients into crystalline salts overcomes crystallization difficulties to improve bioavailability.

R-CHOP monotherapy fails 30% to 50% of non-Hodgkin lymphoma patients. Adding a DHODH inhibitor blocks pyrimidine synthesis, restoring therapeutic efficacy.

Deuterated pipradrol modifies metabolic stability to treat intractable seizures while reducing ataxia and convulsions associated with conventional dosing.

SUCNR1 antagonists block succinate receptor activation, suppressing neuroinflammation and alleviating neurological disease progression.

Natural polyols inhibit microbial growth in aqueous compositions containing natural polymers without artificial preservatives.

A chiral BTK inhibitor modulates adaptive and innate immunity to reduce brain lesions.

Azeotropic distillation removes water during cyclization, eliminating column chromatography and reducing processing time for eluxadoline synthesis.

Selective urea antagonists target prostate receptors while sparing vascular alpha1b receptors, eliminating cardiovascular side effects.

Formula Ia or Ib compounds inhibit SHP2 phosphatase to treat Noonan syndrome and cancer.

Polymorph A crystal structure of an HDAC6 inhibitor resists degradation from light, heat, and humidity while improving therapeutic selectivity.

Oxazole-based TRPV1 antagonists cross the blood-brain barrier to treat chronic pain despite limited central nervous system penetration of prior compounds.

Mannose-functionalized nucleic acid conjugates overcome liver-restricted delivery by targeting CD209 and CD206 C-type lectins on immune cells.

A bispecific antibody binds ErbB-2 and ErbB-3 receptors to block ligand-induced signaling pathways.

D-Boramine corrects BRCA1, BRCA2, and MTHFR mutations by restoring cellular signaling, addressing limitations of complex conventional synthesis methods.

AAV vectors deliver Cas13d guide RNAs to cleave conserved viral RNA, resolving the trade-off between treatment efficacy and variant adaptability.

Cystine molecules bind System xc- transporters on hyperproliferative cells, delivering liposome-encapsulated drugs to reduce nonspecific toxicity.

A piperidino pyrazolopyrimidine compound upregulates Id1 expression to promote pulmonary vascular remodeling.

Encapsulating flavin adenine dinucleotide within gold nanoparticles alters its physicochemical properties to enhance systemic bioavailability and cellular uptake.

C60, serrapeptase, and peptides suspended in lipids resolve the contradiction between composition simplicity and anti-inflammatory effectiveness.

Host-directed arylamide compounds target conserved cellular factors to overcome viral resistance and enable synergistic combination therapies.

A rufinamide solid dispersion uses copovidone carriers to create a stable amorphous pharmaceutical form.

Adjusting pH of lipid peptide hydrogels to weak acidic ranges increases breaking strength, resolving low gel strength issues in stick-shaped applications.

Biodegradable polymer micro-particles encapsulate deoxycholic acid to prevent tissue destruction during subcutaneous injection.

A corticosteroid and insulin analog formulation stimulates bone and cartilage growth through targeted tissue regeneration.

Using R(+) pramipexole lowers eosinophil levels while minimizing adverse side effects compared to racemic mixtures.

Cyclic carbamate modifications in mutant IDH inhibitors overcome resistance mutations while reducing off-target activities for better tolerability.

Fusing Angiopoietin-1 domains with C4BP scaffolds creates stable heptamers that reduce vascular leakage by enhancing solubility and receptor activation.

RNA-based isolation identifies novel AAV capsids that achieve high-efficiency transduction in liver, heart, and brain tissues.

DsiRNA molecules reduce transthyretin protein levels via specific base pairing, avoiding invasive therapies and improving treatment precision.

Anhydrous dasatinib polymorph crystallized from mixed solvents to enhance drug stability and solubility.

Triazole furan compounds extend plasma half-life by resisting enzymatic degradation, sustaining inotropic effects for heart failure treatment.

Novel 6,7-dihydrobenzoquinolizin-2-one derivatives act as pharmaceutical compounds to inhibit viral protein synthesis and secretion.

Phenylquinolinone derivatives act as histamine H3 receptor antagonists to treat neuropathic pain without the addiction risks of opioids.

Segmentation and universality principles guide the development of a stable crystal form that simultaneously inhibits ACC1 and ACC2 to treat metabolic disorders.

Optimized low-substituted hydroxypropylcellulose resolves the trade-off between tablet compressibility and powder flowability for direct tableting.

Inhaled alprazolam bypasses gastrointestinal delays to provide intravenous-like onset, enabling effective seizure prevention during prodrome phases.

Glycolate-linked taxane prodrugs in nanoparticles extend plasma half-life and maintain drug ratios.

Oxime formation and cyclization stabilize intermediates, eliminating chromatography for scalable production.

Laquinimod modulates immune responses to treat uveitis and conjunctivitis, avoiding steroid side effects.

Specific compounds modulate NMDA receptors to treat CNS disorders while reducing excitotoxicity risk through partial activation.

Chiral resolution isolates the active S-enantiomer to maximize kinase inhibition while eliminating inactive R-enantiomer dilution.

Transdermal phytostenone application targets subcutaneous tissue to reduce fat volume, bypassing oral administration delays and high dosage requirements.

Tailored porous substrates reduce average induction time for small organic molecule crystallization by providing specific nucleation sites.

Formula I compounds achieve over 100-fold selectivity for PI3Kδ, reducing side effects from non-selective inhibition while maintaining therapeutic efficacy.

Diltiazem stimulates type III interferon gene expression to enhance antipathogenic epithelial responses.

Controlling aeration timing and pH during fermentation suppresses bitter taste in 1,4-dihydroxy-2-naphthoic acid for food applications.

A human glucokinase mutant gene increases insulin secretion through enhanced enzymatic activity.

Targeted polynucleotide restores wild-type gene expression by downregulating DGKK, NLGN3, and RSBN1L mRNAs without causing genome-wide epigenetic effects.

Process replaces trifluoromethanesulfonic anhydride with 2-nitrobenzenesulfonyl chloride to eliminate column chromatography and resolve low yield issues.

Precise dosage control of compound A balances sleep maintenance against residual sleepiness by optimizing plasma concentration and AUC ranges.

Early-apoptotic mononuclear cells mediate donor-recipient interaction to reduce acute graft-versus-host disease incidence and hepatotoxicity.

A drug-coated balloon catheter delivers therapeutic agents to body lumen strictures via a specialized coating layer.

Optimizing base selection and solvent systems enables scalable production of cathepsin S inhibitors, resolving large-scale synthesis bottlenecks.

Cuprate addition on aziridine phosphoramidates yields amphetamine precursors, removing toxic aziridine impurities.